News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
Newsfile Corp
NEWS
IN THE PRESS
MustGrow Receives Final Approval to List on the TSX Venture Exchange
November 10, 2022
·
4 min read
Business
Nirvana Life Sciences Inc. Announces the Appointment of Sheldon Inwentash to the Board of Directors
November 9, 2022
·
4 min read
Drug Development
Telo Genomics Launches a Minimal Residual Disease Clinical Trial in Multiple Myeloma
November 9, 2022
·
6 min read
Awakn Life Sciences Signs Its Third Licensing Partnership Agreement in North America, and First in New York
November 9, 2022
·
7 min read
Drug Development
Kiora Pharmaceuticals Provides 3rd Quarter 2022 Business and Financial Update; Dosing of KIO-301 in Phase 1 Trial for Retinitis Pigmentosa to Begin Before Year’s End
November 9, 2022
·
8 min read
Drug Development
Adaptimmune Reports Increased Response Rate and Durability of Response in Its Phase 1 SURPASS trial; ORR Now 52% Across Ovarian, Urothelial, and Head & Neck Cancers
November 8, 2022
·
5 min read
Pharm Country
Adaptimmune Reports Third-Quarter Financial Results and Business Update
November 8, 2022
·
14 min read
Cardiol Therapeutics Announces Study Results Demonstrating Protective Effects of CardiolRx(TM) in a Model of Acute Pericarditis
November 7, 2022
·
10 min read
Marvel Biosciences’ Lead Drug Candidate MB-204 Successfully Targets Brain Receptor Important for Alzheimer’s Disease and Depression
November 7, 2022
·
5 min read
Drug Development
Pacylex Will Present Phase 1 Clinical Experience with PCLX-001 and Rationale for Expanding into Acute Myeloid Leukemia Patients at ASH 2022
November 3, 2022
·
2 min read
15 Toronto St., Suite 601 Toronto ON M5C 2E3 US
Tel: 416-806-1750
Visit website
Email Us